Literature DB >> 20021207

Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer.

Elfriede Bollschweiler1, Arnulf H Hölscher, Ralf Metzger.   

Abstract

A review of the literature demonstrated that clinical evaluation cannot be used to determine 'complete response'. The different classification systems of the histopathologic response grading after neoadjuvant radiochemotherapy of esophageal carcinoma are summarized in this report. A systematic review of studies analyzing preoperative chemoradiation of squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the esophagus demonstrated no significant difference in pathologic complete response (pCR) rates between the AC and SCC studies. Analyzing only the applied dose of radiation demonstrated that patients with AC required a higher dose than patients with SCC to achieve complete response. Incorporating chemotherapy administration does not markedly change the difference in required radiation dose. However, when the tumor does respond, the rate of pCR with increasing dosage of chemoradiotherapy increases more rapidly in AC patients than in SCC patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20021207     DOI: 10.2217/fon.09.133

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  15 in total

1.  Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.

Authors:  Ralf Metzger; Ute Warnecke-Eberz; Hakan Alakus; Fabian Kütting; Jan Brabender; Daniel Vallböhmer; Peter P Grimminger; Stefan P Mönig; Uta Drebber; Arnulf H Hölscher; Elfriede Bollschweiler
Journal:  J Gastrointest Surg       Date:  2011-09-29       Impact factor: 3.452

2.  Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?

Authors:  Arta Monir Monjazeb; Greg Riedlinger; Mebea Aklilu; Kim R Geisinger; Girish Mishra; Scott Isom; Paige Clark; Edward A Levine; A William Blackstock
Journal:  J Clin Oncol       Date:  2010-09-27       Impact factor: 44.544

3.  Patients with Non-response to Neoadjuvant Chemoradiation for Esophageal Cancer Have No Survival Advantage over Patients Undergoing Primary Esophagectomy.

Authors:  Guillaume S Chevrollier; Danica N Giugliano; Francesco Palazzo; Scott W Keith; Ernest L Rosato; Nathaniel R Evans Iii; Adam C Berger
Journal:  J Gastrointest Surg       Date:  2019-02-26       Impact factor: 3.452

Review 4.  Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher; Matthias Schmidt; Ute Warnecke-Eberz
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

5.  Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor.

Authors:  Ute Warnecke-Eberz; Seung-Hun Chon; Arnulf H Hölscher; Uta Drebber; Elfriede Bollschweiler
Journal:  Tumour Biol       Date:  2015-01-29

Review 6.  Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer.

Authors:  Jing Liu; Jinbo Yue; Ligang Xing; Jinming Yu
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

Review 7.  The role of induction therapy.

Authors:  Jacob R Moremen; Elaine N Skopelja; DuyKhanh P Ceppa
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 8.  Surveillance or resection after chemoradiation in esophageal cancer.

Authors:  Il-Hwan Park; Jae Y Kim
Journal:  Ann Transl Med       Date:  2018-02

9.  A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.

Authors:  Yuki Hayashi; Lianchun Xiao; Akihiro Suzuki; Mariela A Blum; Bradley Sabloff; Takashi Taketa; Dipen M Maru; James Welsh; Steven H Lin; Brian Weston; Jeffrey H Lee; Manoop S Bhutani; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani
Journal:  Eur J Cancer       Date:  2012-07-31       Impact factor: 9.162

10.  Response evaluation after neoadjuvant chemoradiation by positron emission tomography-computed tomography for esophageal squamous cell carcinoma.

Authors:  Joon Suk Park; Joon Young Choi; Seung Hwan Moon; Yong Chan Ahn; Jeeyun Lee; Dohun Kim; Kwhanmien Kim; Young Mog Shim
Journal:  Cancer Res Treat       Date:  2013-03-31       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.